AGE-RELATED MACULAR DEGENERATION

This early-stage study tests an experimental drug called Kamuvudine-8 (K8) for people with geographic atrophy, a form of advanced dry age-related macular degeneration that causes vision loss. About 30 participants will receive eye injections and be monitored for 26 weeks to check…

This early-stage trial tests a gene therapy called NG101 for wet age-related macular degeneration (AMD), a leading cause of vision loss. About 20 adults aged 50 to 89 who need regular eye injections will receive a one-time gene therapy injection under the retina. The goal is to s…

This early-stage trial tests a gene therapy called KH658 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to deliver a protein that blocks harmful blood vessel growth, potentially reducing the need for frequent eye inj…

This study tests a new treatment called OpRegen, made from stem cells, for people with advanced dry age-related macular degeneration (geographic atrophy). The cells are placed under the retina to replace damaged support cells. The main goal is to check safety, but researchers als…

This study follows 18 people who already received RetinoStat, an experimental gene therapy for wet age-related macular degeneration. The goal is to see if the treatment is safe over the long term by tracking side effects and vision changes. No new participants are being enrolled.

This early-stage trial tests a gene therapy called KH631 for people with wet age-related macular degeneration (AMD), a leading cause of vision loss. The treatment aims to deliver a protein that blocks harmful blood vessel growth, potentially reducing the need for frequent eye inj…

This early-stage study tests the safety of an experimental drug called RO7669330, given as an eye injection, for people with geographic atrophy (a severe form of dry age-related macular degeneration). The study involves 27 participants and will monitor side effects and eye health…

This study evaluates a new system called AVIGA that uses eye-tracking to detect central vision problems in people with wet age-related macular degeneration (AMD). Researchers will compare the system's results with standard tests like eye scans and vision charts. The goal is to se…

This study tests a new, high-resolution imaging device that takes 3D pictures of the back of the eye to detect early signs of age-related macular degeneration (AMD). Researchers will scan 50 adults aged 60 and older with early or intermediate AMD to see if the tool can spot tiny …

This study tests whether giving ONS-5010 (a bevacizumab eye injection) from a pre-filled syringe is as safe as using a standard vial. About 120 people with wet age-related macular degeneration, diabetic macular edema, or branch retinal vein occlusion will take part. The main goal…

This study follows about 110 people who were in the original AREDS or AREDS2 studies for an additional 5 years. The goal is to observe how age-related macular degeneration and cataracts naturally progress over time. Participants get a yearly eye exam and a check-in phone call. No…

This study follows 57 people with age-related macular degeneration (AMD) for up to 5 years to see how their eyes adjust to darkness. Participants, who completed an earlier study, will have regular eye exams and dark adaptation tests. The goal is to better understand how AMD progr…

This study follows 400 people with intermediate age-related macular degeneration (iAMD) for about 3 years. Researchers will track how quickly the disease advances to more severe stages and test new ways to measure vision cell loss. The goal is to better understand the disease, no…

This study follows 217 adults aged 50 and older with or without early to middle dry age-related macular degeneration (AMD) for up to 5 years. Researchers measure how quickly the eyes recover in dim light using a dark adaptation test. The goal is to see if this simple test can hel…

This study tests a new idea: that a certain type of blood vessel growth under the retina in age-related macular degeneration (AMD) may actually help preserve vision, not harm it. Researchers will follow 73 adults aged 50 and older with AMD to compare vision and eye structure in a…

This study tests whether AI software can help eye doctors diagnose four common eye diseases—diabetic retinopathy, age-related macular degeneration, retinal vein occlusion, and glaucoma—more accurately and quickly. Ten doctors will review eye images with and without AI assistance.…